Strategies for switching from conventional antipsychotic drugs or risperidone to olanzapine

Journal of Clinical Psychiatry

Volumn 61, Issue 11, 2000, Pages 833-840

  Kinon, B J ^a   Basson, B R ^a   Gilmore, J A ^a   Malcolm, S ^a   Stauffer, V L ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZATROPINE; BENZATROPINE MESILATE; CLOZAPINE; DIAZEPAM; HALOPERIDOL; OLANZAPINE; PLACEBO; RISPERIDONE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG CHOICE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RELAPSE; SCHIZOPHRENIA; SLEEP DISORDER;

EID: 0033710773     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v61n1105     Document Type: Article

References (25)

1. Neuroleptic discontinuation syndromes
2. Safety and switching issues of novel antipsychotics
3. Changing antipsychotic medication: Guidelines on the transition to treatment with risperidone
4. Observations on switching patients with schizophrenia to risperidone treatment
5. Switching from typical to atypical antipsychotics
6. Switching antipsychotic medications
7. Long-term considerations after switching antipsychotics
8. The routine use of atypical antipsychotic agents, 1: Common treatment goals: Switching of antipsychotics
9. Clinical risk following abrupt and gradual withdrawal of maintenance nearoleptic treatment
10. Withdrawal syndromes associated with antipsychotic drugs
11. Clozapine withdrawal rebound psychosis
12. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia
13. The Brief Psychiatric Rating Scale
14. Mini-Mental State: A practical method for grading the cognitive state of patients for the clinician
15. A rating scale for extrapyramiclal side effects
16. A rating scale for drug-induced akathisia
17. Neuroleptic withdrawal in schizophrenic patients
18. Prolactin shifts after neurolepfic withdrawal
19. Risks of withdrawing antipsychotic medications
20. Olanzapine versus placebo: Results of a double-blind, fixed-dose olanzapine trial
21. Neuroleptic-induced hyperprolactinemia